WELT
WELT (웰트) is a Seoul-based digital therapeutics company whose flagship product, SleepQ, is an MFDS-approved and CE-certified mobile prescription digital therapeutic delivering a 6-week cognitive behavioral therapy program for chronic insomnia patients in South Korea, distributed through university hospital prescriptions and teleconsultation channels with planned European expansion.
- Company typePrivate
- Founded2016
- HeadquartersSeocho, South Korea
- Headcount11–50
- GTM typeB2C
- OfferingSoftware
What WELT does
WELT Corporation (웰트 주식회사) is a South Korea-based digital therapeutics company founded in 2016 and headquartered in Seoul's Gangnam district. The company develops prescription software-based medical treatments, with its flagship product SleepQ (슬립큐) — an MFDS-approved, CE-certified digital therapeutic device for chronic insomnia delivered as a mobile application. SleepQ administers a structured 6-week cognitive behavioral therapy for insomnia (CBT-I) program, combining a proprietary sleep restriction therapy algorithm that generates personalized bedtime and wake-time prescriptions, 1:1 phone coaching with certified sleep counselors (three calls plus night-hour support from 10 PM to 5 AM), AI-assisted consultation via the 'Sleep Doctor Ssam' chatbot, and progressively structured educational content reviewed by psychiatrists. Clinical data cited by the company indicates a 55% or greater reduction in sleep onset latency and treatment effects sustained up to 24 months post-program.
The business model is prescription-based: patients consult a physician in person or via teleconsultation, receive a SleepQ prescription, and pay ₩250,000 KRW for the 6-week program, with Korean national health insurance and supplemental medical insurance reducing patient out-of-pocket to approximately ₩25,000 KRW in many cases. Distribution combines a network of 12+ major Korean university hospital partners (including Seoul National University Hospital, Severance Hospital, and Catholic University Seoul St. Mary's Hospital), a teleconsultation channel, and Google Play / Apple App Store availability for activated prescriptions. WELT is pursuing European expansion through ongoing clinical trials in Germany, and management has publicly indicated pipeline expansion into anxiety, addiction, and depression indications under a 'digital pharmaceutical company' positioning.
WELT firmographics
Firmographics- Name
- WELT
- Legal name
- 웰트 주식회사
- Website
- https://weltcorp.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WELT (웰트) is a Seoul-based digital therapeutics company whose flagship product, SleepQ, is an MFDS-approved and CE-certified mobile prescription digital therapeutic delivering a 6-week cognitive behavioral therapy program for chronic insomnia patients in South Korea, distributed through university hospital prescriptions and teleconsultation channels with planned European expansion.
- Ownership category
- akta.pro rank
WELT industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Pulmonology & Sleep Medicine Telemedicine Platforms (HLALAGAF)
Keywords
Where WELT is headquartered
LocationHeadquarters
- HQ city
- Seocho
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
WELT business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Digital Therapeutics Prescription Program: WELT generates revenue through its SleepQ digital therapeutic program which requires medical prescription. Patients pay for doctor consultation and the 6-week intensive treatment program including personalized sleep management, counselor coaching calls, and daily CBT-I content. The program is partially covered by Korean national health insurance (National Health Insurance) and supplemental insurance (실손 의료보험), creating a hybrid payment model where patients may pay as little as ₩25,000 with insurance coverage.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | SleepQ 6-Week Insomnia Treatment Program |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
WELT product offering
Product offeringCore offering
WELT develops and operates SleepQ (슬립큐), a prescription digital therapeutic mobile application for chronic insomnia treatment. The product delivers a 6-week cognitive behavioral therapy for insomnia (CBT-I) program, including a proprietary sleep restriction algorithm that prescribes personalized bedtime and wake-up times, daily educational content designed by psychiatrists, 1:1 phone coaching with certified sleep counselors, and an AI-powered sleep expert chatbot.
Product overview
WELT operates as a digital therapeutics company with a single flagship product: 슬립큐 (SleepQ), a mobile app-based digital treatment device for insomnia. The product delivers cognitive behavioral therapy for insomnia (CBT-i) through a structured 6-week program, combining 1:1 coaching calls with sleep counselors, personalized bedtime/wake time prescriptions based on sleep restriction therapy algorithms, and educational content designed by psychiatrists. The company positions itself as a 'digital pharmaceutical company' offering prescription-based treatment accessible via telemedicine consultations.
Differentiator
Problem solved
Functional benefit
Brands
- SleepQ (슬립큐): Digital therapeutic application for insomnia treatment using cognitive behavioral therapy (CBT-I). The app received approval from Korea's Ministry of Food and Drug Safety and CE certification for European markets.
Products and services
- SleepQ (슬립큐) A prescription-based digital therapeutic mobile application that delivers a 6-week cognitive behavioral therapy for insomnia (CBT-I) program for adults with chronic insomnia. Includes a proprietary sleep restriction therapy algorithm for personalized bedtime/wake-time prescriptions, 1:1 phone coaching with certified sleep counselors (3 calls), daily educational content reviewed by psychiatrists, relaxation therapy, sleep diary tracking, automated insurance claim document issuance, and an AI chatbot (Sleep Doctor Ssam). Approved by Korean MFDS (제호23-511호) and CE certified for European markets.
Quantifiable outcome
- 55%+ reduction in sleep onset latency (time to fall asleep)
- +2 more outcomes
Companies that use WELT
Customer profileNamed customers12 records
Segments1 record
Ideal customer profiles2 records
WELT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
WELT partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Severance Hospital (세브란스병원)coreSeverance Hospital is a key development and prescription partner for SleepQ. The product was developed with participation of psychiatrists from Severance Hospital's Department of Psychiatry, and it became the first major hospital to prescribe SleepQ following regulatory approval. The hospital serves as a clinical validation partner.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
WELT competitors and assessment
Company assessmentDirect peers
- Somzz: Korea's first MFDS-approved prescription digital therapeutic for insomnia, directly competing with SleepQ in the same Korean hospital channel and reimbursement pathway. WELT explicitly positions itself as the second-mover entrant in this same category.
- Big Health (Sleepio): US/UK-based digital therapeutics company offering Sleepio, a CBT-I program for insomnia — the same evidence-based therapy that SleepQ delivers. Both target clinical-grade sleep treatment through digital channels, with overlapping product functionality and physician-referral GTM.
- Nox Health: Sleep health company offering enterprise sleep programs including CBT-I components, serving employer and healthcare channels. Comparable focus on clinical-grade insomnia intervention via scalable digital delivery.
Broad incumbents
- Pear Therapeutics: Pioneer in prescription digital therapeutics (Somryst for insomnia, reSET for substance use disorder) — direct product precedent for SleepQ's regulatory and commercial model. While Pear filed for bankruptcy in 2023, its Somryst product is the most comparable US FDA-cleared insomnia DTx benchmark.
- Headspace Health: Ginger and Headspace merged to form Headspace Health, offering mental health and sleep content via subscription and employer channels. Operates in overlapping behavioral health and sleep wellness category but with a consumer/employer GTM rather than prescription model.
- Calm: Consumer sleep, meditation, and mental wellness app with extensive sleep-specific content (Sleep Stories). Indirect competitor addressing the same end-customer (insomnia sufferers) via a non-prescription, consumer-led model.
Emerging players
- BetterHelp: Largest online therapy platform offering licensed therapist access, including CBT modalities that overlap with CBT-I. Competes for the same anxiety/insomnia patient population, though via human therapists rather than digital prescription device.
- Dreem: Digital sleep company combining a wearable headband with behavioral sleep programs, including CBT-I elements. Adjacent approach to insomnia treatment through combined hardware/software offering.
- Talkspace: Online therapy platform offering CBT-based behavioral health support that addresses insomnia among other conditions. Comparable telehealth-to-therapy delivery model targeting employer and consumer health benefits markets.
Others
- Oura: Consumer sleep-tracking ring with growing health subscription services. While not a treatment, it serves the same insomnia-prone consumer base and increasingly overlaps via partnerships with sleep coaching and CBT-I content providers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
WELT social profiles
Digital presenceWELT compliance and trust
Trust signalCompliance2 records
WELT financial estimates
Financial estimateRevenue estimate
Valuation estimate
WELT leadership team
Management profileNumber of profiles
Profiles1 record
WELT funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WELT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WELT
What does WELT do?
WELT develops and operates SleepQ (슬립큐), a prescription digital therapeutic mobile application for chronic insomnia treatment. The product delivers a 6-week cognitive behavioral therapy for insomnia (CBT-I) program, including a proprietary sleep restriction algorithm that prescribes personalized bedtime and wake-up times, daily educational content designed by psychiatrists, 1:1 phone coaching with certified sleep counselors, and an AI-powered sleep expert chatbot.
Is WELT a public or private company?
WELT is a private company. It is classified as venture growth investor backed and is currently operating.
When was WELT founded?
WELT was founded in 2016. It employs 11 to 50 people.
Where is WELT based?
WELT is headquartered in Seocho, South Korea, in the Asia region.
How does WELT make money?
One revenue line is on record: digital Therapeutics Prescription Program.
Who are WELT's main competitors?
Direct peers on record are Somzz, Big Health (Sleepio) and Nox Health. Broad incumbents are Pear Therapeutics, Headspace Health and Calm. Emerging players are BetterHelp, Dreem and Talkspace. Oura is listed as an others.
Does WELT have an API?
No public API is recorded for WELT.
What industry is WELT in?
WELT's product category is Digital Therapeutics. Its primary akta.pro industry code is HLALAGAF, Pulmonology & Sleep Medicine Telemedicine Platforms. Its NAICS code is 621420 and its SIC code is 8000.